Table 6 AEs in advanced NSCLC patients who received combination therapy with PD-1 inhibitors and antiangiogenic agents
Adverse events | Any Grade n (%) |  ≥ Grade 3(n/%) |
|---|---|---|
Fatigue | 28(32.9) | 1(1.2) |
Proliferation of capillaries | 27(31.8) | 0(0) |
Hypertension | 25(29.4) | 4(4.7) |
Proteinuria | 23(27.1) | 3(3.5) |
Abnormal thyroid function | 22(25.9) | 2(2.4) |
Hand-foot syndrome | 20(23.5) | 3(3.5) |
Rash | 18(21.2) | 3(3.5) |
Anorexia | 17(20) | 0(0) |
Dyslipidaemia | 15(17.6) | 1(1.2) |
Thrombocytopenia | 14(16.5) | 3(3.5) |
Hepatic dysfunction | 13(15.3) | 2(2.4) |
Oedema | 12(14.1) | 1(1.2) |
Anaemia | 11(12.9) | 1(1.2) |
Diarrhoea | 11(12.9) | 0(0) |
Haemorrhage | 10(11.8) | 0(0) |
Nausea | 10(11.8) | 0(0) |
Pruritus | 9(10.6) | 1(1.2) |
Oral mucositis | 8(9.4) | 0(0) |
Myalgia | 7(8.2) | 0(0) |
Leukopenia | 6(7.1) | 1(1.2) |
Pneumonitis | 5(5.9) | 1(1.2) |
Hypophysitis | 2(2.4) | 0(0) |
Myocarditis | 2(2.4) | 1(1.2) |
Encephalitis | 1(1.2) | 0(0) |